Spyre Therapeutics, Inc. (SYRE) Revenue, Earnings & Financial Statements
$93.81NASDAQ: SYREMarket Cap $8.91B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Spyre Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $155.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Spyre Therapeutics, Inc.: Revenue fell from $5.0M in 2016 to $0 in 2025, a change of -100.0% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -473.3% to -27348.0%, a shift of -26874.6 percentage points; the most recent year shows a net loss of $155.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$5.0M
$5.0M
$4.0M
$0
$0
$19.0M
$2.0M
$1.0M
$0
$0
Operating Expenses
$27.0M
$33.0M
$49.0M
$80.0M
$81.0M
$84.0M
$87.0M
$243.0M
$209.0M
$210.0M
Operating Profit
−$22.0M
−$28.0M
−$45.0M
−$80.0M
−$81.0M
−$66.0M
−$85.0M
−$242.0M
−$209.0M
−$210.0M
Operating Margin
-473.3%
-531.7%
-1169.3%
—
—
-350.3%
-3640.2%
-27348.0%
—
—
Other Income
$0
$0
$1.0M
$2.0M
$1.0M
$0
$1.0M
−$97.0M
$1.0M
$54.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$1.0M
$1.0M
$2.0M
$2.0M
$1.0M
$0
$10.0M
Profit Before Tax
−$22.0M
−$27.0M
−$44.0M
−$78.0M
−$81.0M
−$66.0M
−$84.0M
−$339.0M
−$208.0M
−$155.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
-0.2%
0.2%
0.0%
-0.0%
0.0%
Net Profit
−$22.0M
−$27.0M
−$44.0M
−$78.0M
−$81.0M
−$66.0M
−$84.0M
−$339.0M
−$208.0M
−$155.0M
EPS
−$55.40
−$45.01
−$53.25
−$61.23
−$37.89
−$25.02
−$24.86
−$46.15
−$3.18
−$1.98
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$90.0M
$0
$0
$0
Operating Expenses
$46.0M
$48.0M
$44.0M
$55.0M
$61.0M
$54.0M
$42.0M
$57.0M
$148.0M
$46.0M
$42.0M
$106.0M
Operating Profit
−$46.0M
−$48.0M
−$44.0M
−$55.0M
−$61.0M
−$54.0M
−$42.0M
−$57.0M
−$57.0M
−$46.0M
−$42.0M
−$106.0M
Operating Margin
—
—
—
—
—
—
—
—
-63.2%
—
—
—
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$63.0M
−$44.0M
−$39.0M
−$69.0M
−$56.0M
−$45.0M
−$37.0M
−$11.0M
−$63.0M
−$69.0M
−$36.0M
−$96.0M
Tax rate (%)
0.0%
-0.1%
0.0%
-0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$63.0M
−$44.0M
−$39.0M
−$69.0M
−$56.0M
−$45.0M
−$37.0M
−$11.0M
−$63.0M
−$69.0M
−$36.0M
−$96.0M
EPS
−$2.91
−$1.20
−$0.86
−$1.36
−$0.15
−$0.13
−$0.60
−$0.15
−$0.70
−$0.74
−$0.36
−$0.94
Over the 10 years reported for Spyre Therapeutics, Inc., cash stood at $86.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 13.19 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$67.0M
$56.0M
$78.0M
$83.0M
$162.0M
$110.0M
$71.0M
$342.0M
$608.0M
$778.0M
Current Assets
$66.0M
$55.0M
$77.0M
$75.0M
$150.0M
$99.0M
$62.0M
$342.0M
$608.0M
$778.0M
Cash
$48.0M
$13.0M
$22.0M
$19.0M
$90.0M
$15.0M
$35.0M
$189.0M
$89.0M
$86.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$1.0M
$3.0M
$0
$0
$0
$1.0M
$0
$0
$0
$0
Fixed Assets
$1.0M
$1.0M
$1.0M
$7.0M
$10.0M
$8.0M
$7.0M
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$16.0M
$37.0M
$52.0M
$53.0M
$56.0M
$78.0M
$21.0M
$150.0M
$514.0M
$671.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$4.0M
$6.0M
$10.0M
$23.0M
$22.0M
$26.0M
$21.0M
$158.0M
$91.0M
$63.0M
Current Liabilities
$4.0M
$6.0M
$10.0M
$18.0M
$16.0M
$20.0M
$15.0M
$32.0M
$54.0M
$59.0M
Borrowings
$0
$0
$0
$5.0M
$5.0M
$5.0M
$5.0M
$0
$0
$0
Other Liabilities
$4.0M
$6.0M
$10.0M
$18.0M
$16.0M
$21.0M
$16.0M
$158.0M
$91.0M
$63.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$63.0M
$50.0M
$67.0M
$60.0M
$140.0M
$84.0M
$50.0M
$184.0M
$518.0M
$715.0M
For Spyre Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $169.0M; free cash flow was positive in 0 of 10 years; financing activities used $5.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$19.0M
−$25.0M
−$32.0M
−$66.0M
−$76.0M
−$54.0M
−$80.0M
−$100.0M
−$157.0M
−$169.0M
Investing Cash Flow
−$12.0M
−$23.0M
−$16.0M
−$3.0M
−$12.0M
−$23.0M
$57.0M
−$108.0M
−$353.0M
−$143.0M
Financing Cash Flow
$0
$1.0M
$3.0M
$1.0M
$1.0M
$2.0M
$0
−$5.0M
$6.0M
−$5.0M
Net Cash Flow
$18.0M
−$35.0M
$10.0M
−$3.0M
$71.0M
−$75.0M
$19.0M
$153.0M
−$100.0M
−$4.0M
Free Cash Flow
−$19.0M
−$25.0M
−$33.0M
−$67.0M
−$80.0M
−$54.0M
−$80.0M
−$100.0M
−$157.0M
−$169.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.48
EV / EBITDA
-37.20
FCF Yield
-2.46%
Quick Ratio
27.40
Interest Coverage
—
Return 1Y
285.10%
Return 3Y
815.22%
Return 5Y
-42.71%
Spyre Therapeutics, Inc. (SYRE) financials — frequently asked questions
What is Spyre Therapeutics, Inc.'s annual revenue?
Spyre Therapeutics, Inc. (SYRE) reported annual revenue of $0 in its most recent fiscal year.
What is Spyre Therapeutics, Inc.'s net profit?
Spyre Therapeutics, Inc. (SYRE) reported a net loss of $155.0M in its most recent fiscal year.
What is SYRE EV/EBITDA?
Spyre Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -37.20. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks